We investigated the effect of recombinant tumor necrosis factor-alpha (rTNF-α) on the proliferative response of human umbilical vein endothelial cells (HUVEC) to normal human serum (NHS), in the absence or the presence of interferon (IFN)-γ. rTNF-α significantly impaired NHS-stimulated HUVEC growth at a dose as low as 0.1 U/ml. The inhibitory effect of rTNF-α was dose-dependent up to 50-100 U/ml and was already evident after 2 h of incubation. Doses of rTNF-α in the range of 10 U/ml completely suppressed 3H-thymidine uptake stimulated by 7.5% NHS, and the effect was partially overcome by 10-20% NHS. rTNF-α was not cytotoxic at doses up to 1000 U/ml. rIFN-γ was also effective in suppressing NHS-stimulated3H-thymidine incorporation, and at low doses (0.1 U/ml) rIFN-γ and rTFN-α showed an additive effect. The effect of TFN-α and IFN-γ in antagonizing the proliferative response of vascular endothelium to the variety of growth factors contained in human serum could be relevant in a variety of pathologic conditions involving endothelium damage and proliferation.
BeutlerB., CeramiA.: Cachectin: more than a tumor necrosis factor.N. Engl. J. Med., 316: 379–385, 1987.
2.
BelfioreA., MauerhoffT., Pujol-BorrellR., BadenhoopK., BuscemaM., MirakianR., BottazzoG.F.: De novo HLA Class II and enhanced HLA Class I molecule expression in SV-40 transfected human thyroid epithelial cells.J. Autoimm., 4: 397–414, 1991.
3.
BevilacquaM.P., PoberJ.S., MajeauG.R., FiersW., ContranR.S., GimbroneM.A.: Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin-1. Proc.Natl. Acad. Sci., USA, 83: 4533–4537, 1986.
4.
BroudyV.C., KaushanskyK., SegalG.M., HarlanJ.M., AdamsonJ.W.: Tumour necrosis factor type alpha stimulated human endothelial cells to produce granulocyte/macrophage colony-stimulating factor.Proc. Natl. Acad. Sci., USA, 83: 7467–7471, 1986.
5.
CollinsT., LapierreL.A., FiersW., StromingerJ.L., PoberJ.S.: Recombinant human tumour necrosis factor increases mRNA levels and surface expression of HLA.A, B antigens in vascular endothelial cells and dermal fibroblasts in vitro.Proc. Natl. Acad. Sci. USA, 83: 446–450, 1986.
6.
CreaganE.R., KovachJ.S., MoertelC.G., FrytakS., KvolsL.K.: A phase I clinical trial of recombinant human tumor necrosis factor.Cancer, 62: 2467–2471, 1988.
7.
DelomenieC., Wautier-PepinM.P., ChappeyO., WautierJ.L.: Modulation of human endothelial cell activation by antiproliferative cytokines: exploration of arachidonic acid and intracellular cytokine pathways as possible mechanism of action.Exp. Cell. Res.207: 122–130, 1993.
8.
FransenL., Van der HeydenJ., RuysschaertR., FiersW.: Recombinant tumor necrosis factor: its effects and synergism with interferon-gamma on a variety of normal and transformed human cell lines.Eur. J. Cancer Clin. Oncol., 22: 419–426, 1986.
9.
Frater-SchroderM., RisauW., HallmannR., GautschiP., BohlenP.: Tumour necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro is angiogenic in vivo.Proc. Natl. Acad. Sci., USA, 84: 5277–5281, 1987.
10.
FrieselR., KomoriyaA., MaciagT.: Inhibition of endothelial cell proliferation by gamma interferon.J. Cell. Biol., 104: 689–696, 1987.
11.
GambleJ.R., HarlanJ.M., KlebanoffS.J., LopezS.J., VadasM.A.: Stimulation of the adherence of neutrophils to umbilical vein endothelium by recombinant tumour necrosis factor.Proc. Natl. Acad. Sci., USA, 82: 8667–8671, 1985.
12.
KnauerD.J., CunninghamD.D.: A re-evaluation of the response of human umbilical vein endothelial cells to certain growth factors.J. Cell. Physiol., 117: 397–403, 1983.
13.
LeibovichS.J., PolveriniP.J., ShepardH.M., WisemanD.M., ShivelyV., NuseirN.: Macrophage-induced angiogenesis is mediated by tumour necrosis factor alpha.Nature, 329: 630–632, 1987.
14.
MoserR., SchleiffenbaumB., GroscurthP., FehrJ.: Interleukin I and tumour necrosis factor stimulate human vascular endothelial cells to promote transendothelial neutrophil passage.J. Clin. Invest., 83: 444–455, 1989.
15.
NawrothP.P., BankI., HandleyD., CassimerisJ., ChessL., SternD.: Tumour necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin-I.J. Exp. Med., 163: 1363–1375, 1986.
16.
NoriokaK., BordenE.C., AuerbachR.: Inhibitory effects of cytokines on vascular endothelial cells: synergistic interactions among interferon-gamma, tumor necrosis factor-alpha, and interleukin-1. J.Immunother., 12: 13–18, 1992.
17.
PodorT.J., JirikF.R., LoskutoffD. J., CarsonD.A., LotzM.: Human endothelial cells produce IL-6. Lack of response to exogeneous IL-6. Ann.N. Y. Acad. Sci., 557: 374–385, 1989.
18.
RuggieroV., TavernierJ., FiersW., BaglioniC.: Induction of the syntesis of tumor necrosis factor receptors by interferon-gamma.J. Immunol., 136: 2445–2450, 1986.
19.
SatoN., FotoT., HaranakaK., SatomiN., NariuchiH., Mano-HiranoY., SawasakiY.: Actions of tumour necrosis factor on cultured vascular endothelial cells: morphologic modulation, growth inhibition and cytotoxicity.J. Natl. Cancer Inst., 76: 1113–1121, 1986.
20.
SchweigererL., MalersteinB., GospodarowiczD.: Tumour necrosis factor inhibits the proliferation of cultured capillary endothelial cells.Biochem. Biophys. Res. Comm., 143: 997–1004, 1987.
21.
StolpenA.H., GuinanE.C., FiersW., PoberJ.S.: Recombinant tumour necrosis factor and immune interferon act singly and in combination to reorganize human vascular endothelial cell monolayers.Am. J. Pathol., 123: 16–24, 1986.
22.
van de WielP.A., WeitembergE.S., van der PijlA., BloksmaN.: Factors that define the susceptibility of endothelial cells to tumor necrosis factor and lipid A.Immunopharmacology, 23: 49–56, 1992.
